Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 2Thoracic 1Sarcoma 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 17Neoplasms 6Breast Neoplasms 6Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Prostate Adenocarcinoma 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Oligodendroglioma 1Neuroblastoma 1Metastatic Castration-sensitive Prostate Cancer 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Neoplasms × niraparib × Clear all
NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

GlaxoSmithKline

Phase 1 Terminated
47 enrolled 43 charts
CNSSarcoma

Neoplasms, Neuroblastoma, Osteosarcoma

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Tesaro, Inc.

Phase 1 Completed
60 enrolled 91 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03329001 2024-07-25

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Tesaro, Inc.

Phase 1 Completed
236 enrolled 49 charts
Tumor-Agnostic

Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Tesaro, Inc.

Phase 2 Completed
53 enrolled 35 charts
Tumor-Agnostic

Neoplasms

NCT02657889 2022-12-01

TOPACIO

Tesaro, Inc.

Phase 1/2 Completed
122 enrolled 29 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03359850 2021-05-28

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

Tesaro, Inc.

Phase 1 Completed
17 enrolled 35 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡